公开(公告)号：US11364244B2

公开(公告)日：2022-06-21

申请号：US16607266

申请日：2019-04-17

申请人： ONCOCROSS CO., LTD.

发明人： Yi-Rang Kim ,  Jin-Woo Choi

IPC分类号： A61K31/522 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06 ,  A61K31/19 ,  A61K31/137 ,  A23L33/10 ,  A61P21/00 ,  A61P21/04

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.

公开(公告)号：US11364237B2

公开(公告)日：2022-06-21

申请号：US16484305

申请日：2018-02-06

申请人： ONCOCROSS CO., LTD.

发明人： Yi-Rang Kim

IPC分类号： A61K31/4965 ,  A61P35/00 ,  A61K31/085 ,  A61K31/195 ,  A61K31/4706

摘要： The present invention relates to an anticancer and metastasis inhibiting effect by treatment with chlorphenesin, chloroquine, and chloropyrazine alone or in combination. Chlorphenesin, chloroquine, or chloropyrazine show the effect of killing cancer cells and inhibiting proliferation, and metastasis of cancer cells and particularly, a combination thereof is identified to have synergism. Cancer can be effectively prevented or treated by administering chlorphenesin, chloroquine, and chloropyrazine alone or in combination thereof.

公开(公告)号：US12064435B2

公开(公告)日：2024-08-20

申请号：US17744339

申请日：2022-05-13

申请人： ONCOCROSS CO., LTD.

发明人： Yi-Rang Kim ,  Jin-Woo Choi

IPC分类号： A61K31/522 ,  A23L33/10 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06 ,  A61P21/00 ,  A61P21/04

CPC分类号： A61K31/522 ,  A61K31/197 ,  A61K31/437 ,  A61K45/06

摘要： The present invention relates to a pharmaceutical composition for prevention or treatment of a muscular disease, the composition comprising dimenhydrinate, harmol and/or calcium pantothenate as active ingredients. Application of dimenhydrinate, harmol, and calcium pantothenate individually has an effect of promoting myoblast proliferation and differentiation. In particular, the combination thereof has the effect of synergistically increasing the effect of promoting myoblast proliferation and differentiation. Thus, dimenhydrinate, harmol and/or calcium pantothenate may be usefully used alone or in combination for the prevention or treatment of muscular diseases, in particular sarcopenia.

公开(公告)号：US20220273642A1

公开(公告)日：2022-09-01

申请号：US17742296

申请日：2022-05-11

申请人： ONCOCROSS CO., LTD.

发明人： Yi-Rang Kim ,  Sang Yun Park ,  Ga Eul Yang ,  Seung Jun Lee

IPC分类号： A61K31/4706 ,  A61K31/325 ,  A61P35/04

摘要： The present disclosure relates to an effect of inhibiting cancer metastasis by treatment of chlorphenesin and hydroxychloroquine alone or in combination. Chlorphenesin or hydroxychloroquine has the effect of inhibiting the metastasis and invasion of cancer cells. In particular, since it was identified that a combination thereof has a synergistic action, it is possible to effectively prevent or treat cancer metastasis by administering chlorphenesin and hydroxychloroquine respectively or in combination thereof.